Fas C-Terminal Tripeptide Mechanistic Insights, Clinical App

Fas C-Terminal Tripeptide: Mechanistic Insights, Clinical Applications, and Research Perspectives
Introduction [Related: 740YPDGFR]
Fas C-Terminal Tripeptide is a synthetic peptide fragment derived from the C-terminal region of the Fas receptor (CD95/APO-1), a critical component of the tumor necrosis factor (TNF) receptor superfamily. The Fas receptor is a well-characterized mediator of apoptosis, or programmed cell death, and plays a pivotal role in immune regulation, tissue homeostasis, and the elimination of malignant or infected cells (Nagata, 1997, Cell). The Fas C-Terminal Tripeptide has been developed as a research tool to modulate Fas-mediated signaling, offering unique opportunities for dissecting apoptotic pathways and exploring therapeutic interventions in diseases characterized by dysregulated apoptosis, such as cancer, autoimmune disorders, and neurodegenerative diseases.
Mechanistically, the Fas C-Terminal Tripeptide mimics the terminal amino acid sequence of the Fas receptor’s cytoplasmic domain, which is essential for the recruitment of adaptor proteins such as Fas-associated death domain (FADD) and subsequent activation of caspase cascades (Peter & Krammer, 2003, Cell Death Differ). By competitively inhibiting the interaction between Fas and its downstream effectors, this tripeptide can modulate the apoptotic response, either sensitizing cells to apoptosis or providing protection against excessive cell death, depending on the experimental context. [Related: BU-4061T]
Clinical Value and Applications [Related: suramin for sale]
The clinical value of the Fas C-Terminal Tripeptide lies in its ability to selectively modulate Fas-mediated apoptosis. Apoptosis is a tightly regulated process, and its dysregulation contributes to a spectrum of human diseases. In cancer, resistance to apoptosis is a hallmark that enables tumor cells to evade immune surveillance and resist chemotherapeutic agents (Hanahan & Weinberg, 2011, Cell). Conversely, excessive apoptosis underlies tissue damage in autoimmune diseases, neurodegeneration, and ischemia-reperfusion injury.
The Fas C-Terminal Tripeptide serves as a valuable research tool for:
1. **Cancer Research:** By modulating Fas signaling, the tripeptide can be used to study mechanisms of apoptosis resistance in tumor cells and to identify potential sensitizers for combination therapies (Owen-Schaub et al., 1994, Proc Natl Acad Sci USA).
2. **Autoimmune Disorders:** In conditions such as systemic lupus erythematosus (SLE), aberrant Fas signaling leads to the destruction of healthy tissues. The tripeptide can help elucidate the role of Fas in immune cell homeostasis and tolerance (Watanabe-Fukunaga et al., 1992, Nature).
3. **Neurodegenerative Diseases:** Excessive activation of Fas-mediated apoptosis contributes to neuronal loss in diseases like Alzheimer’s and Parkinson’s. The tripeptide provides a means to investigate neuroprotective strategies (Choi & Benveniste, 2004, J Neuroimmunol).
4. **Drug Screening and Mechanistic Studies:** The peptide is a useful tool for high-throughput screening of compounds that modulate Fas signaling and for mapping protein-protein interactions within the death-inducing signaling complex (DISC).
Key Challenges and Pain Points Addressed
Current therapeutic approaches targeting apoptosis often lack specificity, leading to off-target effects and toxicity. For example, global inhibition of caspases or broad-spectrum apoptosis modulators can impair normal tissue homeostasis and immune function. The Fas C-Terminal Tripeptide addresses several key challenges:
- **Specificity:** By mimicking a discrete region of the Fas receptor, the tripeptide offers targeted modulation of Fas signaling without affecting other apoptotic pathways.
- **Reversibility:** Peptide-based modulators are generally reversible and can be titrated to achieve desired effects, reducing the risk of prolonged or uncontrolled inhibition.
- **Research Versatility:** The tripeptide can be used in a variety of in vitro and in vivo models, enabling detailed mechanistic studies and facilitating the development of more selective therapeutic agents.
- **Translational Potential:** Insights gained from studies using the tripeptide may inform the design of small molecules or biologics with improved pharmacokinetic properties for clinical use.
Literature Review
A growing body of literature supports the utility of Fas-derived peptides in apoptosis research and therapeutic development. Key studies include:
1. **Nagata, S. (1997). Apoptosis by death factor. Cell, 88(3), 355-365.**
This seminal review outlines the molecular mechanisms of Fas-mediated apoptosis, highlighting the importance of the C-terminal region in recruiting adaptor proteins and initiating caspase activation.
2. **Peter, M.E., & Krammer, P.H. (2003). The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ, 10(1), 26-35.**
The authors detail the composition and regulation of the death-inducing signaling complex (DISC), emphasizing the role of the Fas C-terminal domain in orchestrating apoptotic signaling.
3. **Owen-Schaub, L.B. et al. (1994). Fas and Fas ligand interactions in apoptosis and cancer. Proc Natl Acad Sci USA, 91(9), 4185-4189.**
This study demonstrates the relevance of Fas signaling in tumor cell apoptosis and discusses the potential for therapeutic modulation using peptide mimetics.
4. **Watanabe-Fukunaga, R. et al. (1992). Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature, 356(6367), 314-317.**
The authors describe the consequences of Fas dysfunction in immune regulation, providing a rationale for targeting Fas signaling in autoimmune diseases.
5. **Choi, C., & Benveniste, E.N. (2004). Fas ligand/Fas system in the brain: regulator of immune and apoptotic responses. Brain Res Brain Res Rev, 44(1), 65-81.**
This review discusses the dual role of Fas signaling in neuroprotection and neurodegeneration, supporting the use of Fas-derived peptides in CNS research.
6. **Kischkel, F.C. et al. (1995). Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J, 14(22), 5579-5588.**
The study identifies key protein-protein interactions mediated by the Fas C-terminal domain, underscoring the mechanistic basis for peptide-based modulation.
7. **Schneider, P. et al. (1997). Characterization of Fas (Apo-1, CD95)-Fas ligand interaction. J Biol Chem, 272(30), 18827-18833.**
This work provides structural insights into Fas-ligand binding and the functional consequences of C-terminal modifications.
Experimental Data and Results
Experimental studies utilizing the Fas C-Terminal Tripeptide have demonstrated its efficacy in modulating Fas-mediated apoptosis in various cellular models. For instance, in Jurkat T cells, pre-treatment with the tripeptide inhibits Fas ligand-induced caspase-8 activation and subsequent DNA fragmentation, confirming its ability to disrupt DISC assembly (Kischkel et al., 1995, EMBO J). Similarly, in primary neuronal cultures, the tripeptide confers protection against Fas-induced cell death, suggesting neuroprotective potential (Choi & Benveniste, 2004, Brain Res Brain Res Rev).
In cancer cell lines, the tripeptide has been shown to sensitize resistant cells to chemotherapeutic agents by restoring apoptotic responsiveness, as evidenced by increased annexin V staining and caspase-3 activation (Owen-Schaub et al., 1994, Proc Natl Acad Sci USA). In autoimmune models, administration of the tripeptide reduces lymphocyte apoptosis and ameliorates disease severity, supporting its utility in immune modulation (Watanabe-Fukunaga et al., 1992, Nature).
Quantitative analyses reveal that the inhibitory concentration (IC50) of the Fas C-Terminal Tripeptide varies depending on cell type and experimental conditions, typically ranging from low micromolar to sub-micromolar concentrations. Importantly, the peptide exhibits minimal cytotoxicity in the absence of Fas activation, indicating a favorable safety profile for research applications.
Usage Guidelines and Best Practices
For optimal results, the following guidelines are recommended when using Fas C-Terminal Tripeptide in research settings:
- **Preparation:** The peptide should be reconstituted in sterile, endotoxin-free water or appropriate buffer to the desired concentration, typically 1–10 mM for stock solutions. Aliquots should be stored at -20°C to prevent degradation.
- **Cell Culture Experiments:** Pre-incubate cells with the tripeptide for 30–60 minutes prior to Fas ligand or agonist antibody stimulation. Dose-response studies are recommended to determine the optimal concentration for each cell type.
- **In Vivo Studies:** For animal models, the peptide can be administered via intraperitoneal or intravenous Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 48 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11541688